FDA grants Fast Track designation to INmune Bio's XPro for early Alzheimer's disease

Inmune Bio, Inc.

Fast Track covers XPro for early Alzheimer's disease (MCI due to AD and mild AD dementia).
XPro is a selective soluble TNF inhibitor targeting neuroinflammation; no approved therapy targets this pathway.
Designation provides more frequent FDA interactions and eligibility for Rolling Review.
Phase 2b/3 registrational trial planned as seamless adaptive design using EMACC and pTau217.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.